Clinical analysis of interventional therapy for primary hepatic carcinoma with portal vein tumor thrombus in 66 cases

Objective To investigate the efficacy and safety of the interventional treatment on hepatic cell carcinoma( HCC) with portal vein tumor thrombus( PVTT). Methods Sixty-six cases of patients with HCC were selected,and divided into two groups: combined treatment group and TACE group according to random number table method. The clinical efficacy between two groups were compared. Results After six months,the efficiency rate and reduced rate of PVTT in combined treatment group were significantly higher than TACE group( P 0. 05). The median survival time and six months,1-year,2-year survival rates in combined group were higher than that of TACE group( P 0. 05). After 1 month treatment,the incidence of adverse reaction was 36. 36% in combined group,and significantly lower than TACE group( 81. 82%)( P 0. 05). After six months treatment,the AFP in combined group and TACE group were( 425. 36 ±113. 32) IU / ml and( 725. 32 ± 113. 32) IU / ml( P 0. 05),respectively. Conclusion TACE combined with PVC treating HCC with PVTT can improve the effective treatment in patients with advanced primary liver cancer,improve the patient's quality of life,and also can reduce the toxicity of anticancer drugs produced and the expression of AFP.